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IntroducMon	  
•  PCOA	  exam	  is	  administered	  annually	  to	  P3	  students	  in	  January	  at	  the	  
Wegmans	  School	  of	  Pharmacy.	  	  
	  
•  PCOA	  provides	  a	  forma?ve	  assessment	  to	  evaluate	  student	  progress	  in	  
rela?on	  to	  the	  pharmacy	  curriculum.	  	  
	  
•  The	  School	  uses	  results	  from	  the	  PCOA	  to:	  
1.  Provide	  an	  external	  check	  on	  our	  internal	  assessment	  of	  
achievement	  of	  curricular	  outcomes	  
2.  Recognize	  students	  who	  achieve	  >	  90th	  percen?le	  




•  The	  purpose	  of	  the	  study	  was	  to	  respond	  to	  students’	  inquiry	  
regarding	  the	  rela?onship	  between	  student	  performance	  on	  the	  PCOA	  
and	  performance	  and	  on	  the	  NAPLEX	  administered	  post-­‐gradua?on.	  
Methods	  
	  
•  PCOA	  scores	  for	  two	  of	  the	  four	  content	  areas	  (Pharmaceu?cal	  
Sciences	  and	  Clinical	  Sciences),	  resul?ng	  from	  administra?on	  of	  the	  
assessment	  in	  2012	  and	  2013	  were	  compared	  to	  the	  same	  student	  
scores	  for	  the	  2013	  and	  2014	  NAPLEX	  taken	  post-­‐gradua?on.	  	  
	  
•  Pearson	  product-­‐moment	  correla?on	  coeﬃcient	  was	  calculated	  to	  
measure	  the	  linear	  correla?on	  between	  the	  two	  sets	  of	  exam	  scores;	  
Linear	  regression	  was	  used	  to	  explain	  the	  predictor,	  PCOA,	  variability	  




	  	  	  
Variable	  	  
(n	  =	  105)	  






392.1	  (±	  51.4)	   237	   524	  
Clinical	  Science	  	   414.4	  (±	  54.9)	   288	   582	  
Pharmaceu?cal	  
Science	  +	  Clinical	  
Science	  	  
806.5	  (±	  94.7)	   575	   1097	  
Total	  PCOA	  Score	   392.9	  (±	  43.1)	   296	   535	  






















Clinical	  Science	  	   0.585*	   1.0000	  
Pharmaceu?cal	  
Science	  +	  Clinical	  
Science	  
0.883*	   0.898*	   1.0000	  
Total	  PCOA	  
score	  
0.875*	   0.843*	   0.964*	   1.000	  
NAPLEX	  Score	   0.534*	   0.486*	   0.572*	   0.563	   1.000	  
*Pearson’s	  Product	  Moment	  Correla?on	  Coeﬃcient	  	  	  	  
PCOA	  Content	  Areas	  	   Revised	  NAPLEX	  Content	  Areas	  	  
•  Basic	  Biomedical	  
Sciences	  
•  Pharmaceu?cal	  Sciences	  
•  Social/Behavioral/
Administra?ve	  Sciences	  	  
•  Clinical	  Sciences	  	  
•  Ensure	  Safe	  and	  Eﬀec?ve	  
Pharmacotherapy	  and	  Health	  Outcomes	  
•  Safe	  and	  Accurate	  Prepara?on,	  
Compounding,	  Dispensing	  and	  
Administra?on	  of	  Medica?ons	  and	  
Provision	  of	  Healthcare	  Products	  	  
•  Predicted	  NAPLEX	  =	  	  	  
51.4	  +	  0.70	  (Pharmaceu?cal	  Science	  +	  Clinical	  Science)	  	  	  
R2	  =	  0.328	  
Conclusions	  
•  There	  was	  a	  strong	  posi?ve	  correla?on	  between	  the	  content	  areas	  of	  
the	  PCOA	  (Pharmaceu?cal	  Sciences	  and	  Clinical	  Sciences)	  and	  
NAPLEX	  scores,	  r	  =	  0.572,	  p	  <	  0.0005	  
	  
•  32.8%	  of	  the	  varia?on	  in	  NAPLEX	  scores	  can	  be	  explained	  by	  the	  
content	  areas	  of	  Pharmaceu?cal	  Sciences	  and	  Clinical	  Sciences	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